This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Tn antigen; toll-like receptor 9 (TLR9)	<p>Mouse studies suggest a cancer vaccine incorporating tumor-associated carbohydrate mimetics could help treat cancer. The vaccine comprised a cyclopeptide carrier linked to four Tn antigen mimetics and an ovalbumin-based immunostimulating peptide. In mouse models of cancer, subcutaneous immunization with the vaccine plus a TLR9-agonizing adjuvant induced long-lived IgG and IgM antibodies that bound tumor-associated antigens in human and mouse cancer cell lines. In mice with subcutaneous teratocarcinoma xenograft tumors, immunization with the vaccine plus adjuvant decreased tumor size and increased survival compared with immunization using adjuvant alone or vehicle. Next steps could include testing the vaccine in other models of cancer.</p> <p>SciBX 7(39); doi:10.1038/scibx.2014.1147 Published online Oct. 9, 2014</p>	Patent and licensing status unavailable	<p>Richichi, B. <i>et al. Angew. Chem. Int. Ed.</i>; published online Aug. 28, 2014; doi:10.1002/anie.201406897 Contact: Lbachir BenMohamed, University of California, Irvine School of Medicine, Irvine, Calif. e-mail: lbenmoha@uci.edu Contact: Olivier Renaudet, University of Grenoble Alpes, Grenoble, France e-mail: olivier.renaudet@ujf-grenoble.fr Contact: Cristina Nativi, University of Florence, Florence, Italy e-mail: cristina.nativi@unifi.it</p>